Evidence map›Paper›PMID 25220020›Full record

Trial reportDrug testing and analysis2015

Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking.

Dayong Lee, Ryan Vandrey, Damodara R Mendu, Jeannie A Murray, Allan J Barnes, Marilyn A Huestis

Abstract readClinical Trial
In one paragraph

Trial report in Drug testing and analysis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Detection of ΔDrug testing and analysis · 2024
    Trial
  2. Detection of ΔDrug testing and analysis · 2019
    Trial
  3. Article
  4. Article
  5. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Dayong LeeChemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD, USA.
Ryan VandreyJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Damodara R MenduChemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD, USA.
Jeannie A MurrayJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Allan J BarnesChemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD, USA.
Marilyn A HuestisChemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD, USA.
National Institute on Drug Abuse · USJohns Hopkins University · US

Funding

Pharmacokinetics And Pharmacodynamics Of Smoked Drugs Of AbuseZIADA000413 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SCHEIDWEILER, KARL · 2009 to 2016
$6.0M
Detection Of Drugs Of Abuse In Alternative Biological Fluids And TissuesZIADA000412 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SCHEIDWEILER, KARL · 2009 to 2016
$3.9M
Efficacy and Safety of Dronabinol (Oral THC) for Treating Cannabis DependenceR01DA025044 · NIDA · JOHNS HOPKINS UNIVERSITY · PI VANDREY, RYAN G · 2009 to 2012
$2.0M
Intramural NIH HHS ZIA DA000412Intramural NIH HHS ZIA DA000413NIDA NIH HHS R01 DA025044
6 · The paper itself

Abstract

Oral fluid (OF) offers a simple, non-invasive, directly observable sample collection for clinical and forensic drug testing. Given that chronic cannabis smokers often engage in drug administration multiple times daily, evaluating OF cannabinoid pharmacokinetics during ad libitum smoking is important for practical development of analytical methods and informed interpretation of test results. Eleven cannabis smokers resided in a closed research unit for 51 days, and underwent four, 5-day oral delta-9-tetrahydrocannabinol (THC) treatments. Each medication period was separated by 9 days of ad libitum cannabis smoking from 12:00 to 23:00 h daily. Ten OF samples were collected from 9:00-22:00 h on each of the last ad libitum smoking days (Study Days 4, 18, 32, and 46). As the number of cannabis cigarettes smoked increased over the study days, OF THC, cannabinol (CBN), and 11-nor-9-carboxy-THC (THCCOOH) also increased with a significant effect of time since last smoking (Δtime; range, 0.0-17.4 h) and ≥88% detection rates; concentrations on Day 4 were significantly lower than those on Days 32 and 46 but not Day 18. Within 30 min of smoking, median THC, CBN, and THCCOOH concentrations were 689 µg/L, 116 µg/L, and 147 ng/L, respectively, decreasing to 19.4 µg/L, 2.4 µg/L, and 87.6 ng/L after 10 h. Cannabidiol and 11-hydroxy-THC showed overall lower detection rates of 29 and 8.6%, respectively. Cannabinoid disposition in OF was highly influenced by Δtime and composition of smoked cannabis. Furthermore, cannabinoid OF concentrations increased over ad libitum smoking days, in parallel with increased cannabis self-administration, possibly reflecting development of increased cannabis tolerance.

Indexed as

Administration, OralAdultCannabidiolCannabinoidsCannabinolDronabinolFemaleHumansMaleMarijuana SmokingMiddle AgedSalivaSelf AdministrationSubstance Abuse DetectionTime Factors11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acidCannabidiolCannabinoidsCannabinolDronabinolcannabinoidcannabisdelta-9-tetrahydrocannabinoloral fluid

Identifiers

PMID25220020
PMCPMC4362971
OpenAlexW2107640341

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.